Open AccessAutoantibody Against Ferritin Light Chain is a Serum Biomarker for the Detection of Liver Cirrhosis but Not Liver Cancer
Author(s) -
Pengfei Ren,
Keyan Wang,
Jie Ma,
Xiaoqin Cao,
Jiuzhou Zhao,
Chengzhi Zhao,
Yongjun Guo,
Hua Ye
Publication year - 2022
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s352057
Subject(s) - cirrhosis , hepatocellular carcinoma , gastroenterology , biomarker , medicine , ferritin , autoantibody , receiver operating characteristic , stage (stratigraphy) , cancer , immunology , antibody , chemistry , biology , paleontology , biochemistry
Ferritin is a protein that plays an important role in iron metabolism, it consists of two subunits: heavy chain (FTH) and light chain (FTL). Elevated expression of FTL is observed in multiple malignancies. Recent studies have found that the frequency of circulating autoantibody against FTL (anti-FTL) increased significantly in hepatocellular carcinoma (HCC). The aim of this study is to verify circulating anti-FTL as a biomarker for the early detection of HCC.